Supplemental Material for "Increased risk of COVID-19-related hospitalization in patients with hidradenitis suppurativa compared with controls"

Table S1. Patient eligibility flowchart – Page 2
Table S2. Definitions for exposures, outcomes, and covariates – Pages 3-7
Table S3. Risk of hospitalization for COVID-19 in HS patients and control patients – Page 8
Table S4. Demographic and clinical characteristics according to treatment group – Pages 9-10
Table S5. Incidence of COVID-19 hospitalization among hidradenitis suppurativa patients according to
use of biologics and traditional immunosuppressives – Page 11
Table S6. Complete demographic and clinical characteristics of patients with HS and controls – Pages 12-
13